• Cell Therapy R&D (CAR-T, CAR-NK, TCR-T, Stem Cells).• Gene editing technologies.• Scientific due diligence for combinatorial cancer immunotherapies.• Target and epitope identification for vaccines, CAR-T and TCR-T cell-based therapies.• Cancer vaccine R&D.• Scientific due diligence in immuno-oncology.

Cancer T cell therapy R&D. TCR-T & CAR-T cell therapy. IND-enabling R&D. Cell Engineering.

• In vivo Immunopharmacology - Mouse Preclinical Trials.• Combinatorial cancer immunotherapy.• Preclinical Development of Immune Checkpoint Modulators.• Molecular and Cellular Profiling of Syngeneic and Humanized Mouse Models to Provide Predictive and Prognostic Biomarkers for Cancer Immunotherapy.• Antigen and Epitope Discovery for Vaccine- and Cell-based Cancer Therapies.• Novel Cancer Vaccine Platforms.• Cell systems engineering for validation purposes.• IP-driven Multidisciplinary Discovery Research.• Building External Research Collaborations and Partnerships.• Multidisciplinary approach to immuno-oncology R&D.

• Novel Immuno-oncology platforms.• Identification of novel mechanisms of immune tolerance to tumor antigens.• Cancer vaccine development.• Personalized cancer immunotherapy.• Lymphocyte and Dendritic cell biology.• Immunoinformatics.• Immunoassays.• Immunomonitoring.• Biomarker research (Tumor, blood, urine markers).

Develop novel cancer vaccine platforms and investigate mechanisms of immune tolerance to tumor antigens.

Laboratory head, Translational Cancer Immunology & Immunotherapy.

- Respiratory Immunology.- Mouse models of allergic asthma, pollution, bacterial and viral infections.- Scavenger receptor biology and innate-adaptive immune bridging.